United Therapeutics Corporation Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
United Therapeutics Corporation (UTHR) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 100.00 thousand shares for the 6-month period ending 2016-06-30, per its 10-Q filed 2017-07-27.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2018-02-21
- United Therapeutics Corporation incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2016-03-31 was 100.00K shares.
- United Therapeutics Corporation incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2015-09-30 was 500.00K shares.
- United Therapeutics Corporation incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2015-06-30 was 1.00M shares, a 62.16% decline year-over-year.
- United Therapeutics Corporation incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2014-06-30 was 2.64M shares, a 94.05% increase year-over-year.
- United Therapeutics Corporation incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2015 was 900.00K shares, a 65.38% decline from fiscal 2014.
- United Therapeutics Corporation incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2014 was 2.60M shares, a 49.77% increase from fiscal 2013.
- United Therapeutics Corporation incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2013 was 1.74M shares, a 696.33% increase from fiscal 2012.
- United Therapeutics Corporation incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2012 was 218.00K shares, a 61.69% decline from fiscal 2011.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2016-06-30 | 100.00K shares 10-Q · filed 2017-07-27 | |||||||
| 2016-03-31 | 100.00K shares 10-Q · filed 2017-04-26 | |||||||
| 2015-12-31 | 900.00K shares 10-K · filed 2018-02-21 | 915.00K shares 10-K · filed 2016-02-25 | ||||||
| 2015-09-30 | 500.00K shares 10-Q · filed 2016-10-27 | 479.00K shares 10-Q · filed 2015-10-27 | 1.10M shares 10-Q · filed 2016-10-27 | 1.14M shares 10-Q · filed 2015-10-27 | ||||
| 2015-06-30 | 1.00M shares 10-Q · filed 2016-07-28 | 1.06M shares 10-Q · filed 2015-07-28 | 1.50M shares 10-Q · filed 2016-07-28 | 1.47M shares 10-Q · filed 2015-07-28 | ||||
| 2014-12-31 | 2.60M shares 10-K · filed 2017-02-22 | 2.63M shares 10-K · filed 2015-02-24 | ||||||
| 2014-09-30 | 2.75M shares 10-Q · filed 2015-10-27 | |||||||
| 2014-06-30 | 2.64M shares 10-Q · filed 2015-07-28 | 2.72M shares 10-Q · filed 2015-07-28 | ||||||
| 2014-03-31 | 2.80M shares 10-Q · filed 2015-04-28 | |||||||
| 2013-12-31 | 1.74M shares 10-K · filed 2016-02-25 | |||||||
| 2013-09-30 | 1.82M shares 10-Q · filed 2014-10-28 | 1.39M shares 10-Q · filed 2014-10-28 | ||||||
| 2013-06-30 | 1.36M shares 10-Q · filed 2014-07-29 | 1.12M shares 10-Q · filed 2014-07-29 | ||||||
| 2013-03-31 | 826.00K shares 10-Q · filed 2014-04-29 | |||||||
| 2012-12-31 | 218.00K shares 10-K · filed 2015-02-24 | |||||||
| 2012-09-30 | 662.00K shares 10-Q · filed 2013-10-29 | 136.00K shares 10-Q · filed 2013-10-29 | ||||||
| 2012-03-31 | 49.00K shares 10-Q · filed 2013-04-25 | |||||||
| 2011-12-31 | 569.00K shares 10-K · filed 2014-02-25 | |||||||
| 2011-09-30 | 1.49M shares 10-Q · filed 2012-11-01 | 2.44M shares 10-Q · filed 2012-11-01 | ||||||
| 2011-06-30 | 2.70M shares 10-Q · filed 2012-07-26 | 2.81M shares 10-Q · filed 2012-07-26 | ||||||
| 2011-03-31 | 2.91M shares 10-Q · filed 2012-04-26 | |||||||
| 2010-12-31 | 2.13M shares 10-K · filed 2013-02-26 | |||||||
| 2010-09-30 | 1.66M shares 10-Q · filed 2011-10-27 | 2.00M shares 10-Q · filed 2011-10-27 | ||||||
| 2010-06-30 | 2.02M shares 10-Q · filed 2011-07-28 | 2.15M shares 10-Q · filed 2011-07-28 | ||||||
| 2009-12-31 | 399.00K shares 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |